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Abstract: The importance of astrocytic L-lactate (LL) for normal functioning of neural circuits such
as those regulating learning/memory, sleep/wake state, autonomic homeostasis, or emotional
behaviour is being increasingly recognised. L-Lactate can act on neurones as a metabolic or redox
substrate, but transmembrane receptor targets are also emerging. A comparative review of the
hydroxy-carboxylic acid receptor (HCA1, formerly known as GPR81), Olfactory Receptor Family
51 Subfamily E Member 2 (OR51E2), and orphan receptor GPR4 highlights differences in their
LL sensitivity, pharmacology, intracellular coupling, and localisation in the brain. In addition,
a putative Gs-coupled receptor on noradrenergic neurones, LLRx, which we previously postulated,
remains to be identified. Next-generation sequencing revealed several orphan receptors expressed
in locus coeruleus neurones. Screening of a selection of these suggests additional LL-sensitive
receptors: GPR180 which inhibits and GPR137 which activates intracellular cyclic AMP signalling
in response to LL in a heterologous expression system. To further characterise binding of LL at
LLRx, we carried out a structure–activity relationship study which demonstrates that carboxyl and
2-hydroxyl moieties of LL are essential for triggering D-lactate-sensitive noradrenaline release in locus
coeruleus, and that the size of the LL binding pocket is limited towards the methyl group position.
The evidence accumulating to date suggests that LL acts via multiple receptor targets to modulate
distinct brain functions.
Keywords: L-lactate; hydroxy-carboxylic acid receptor; OR51E2; GPR4; GPR137; cAMP; locus
coeruleus; noradrenaline; next generation sequencing; structure–activity relationship
1. Introduction
Astrocytes, the electrically nonexcitable “cousins” of neurones, are strategically placed at the
interface between the periphery and neuronal networks of the central nervous system. Among other
functions, they handle the import and distribution of glucose, the main energy substrate used by the
brain, as well as its storage in the form of glycogen [1]. Glycolytic breakdown of glucose to pyruvate,
and its subsequent conversion to L-lactate (LL), yields two units of ATP for intracellular energy transfer
or, alternatively, for use as a transmitter. If glycolysis is followed by oxidative phosphorylation, nearly
20 times as much ATP can be produced. This, however, does not mean that almost all ATP in the
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cell is delivered by mitochondria. In fact, since glycolysis is very fast compared to the mitochondrial
oxidation of pyruvate, the contribution of glycolysis to the pool of ATP may be comparable to that
originating from oxidative phosphorylation [2], especially during peaks of high metabolic demand.
In spite of the obvious discrepancy in energy efficiency, the brain produces large amounts of LL,
much of which, surprisingly, is drained into the peripheral circulation [3]. The energetic or functional
advantages of this metabolic imbalance are still controversial.
Average physiological extracellular levels of LL reported for the brain are in the sub- to low mM
range, but they respond dynamically to plasma LL concentrations, central availability of oxygen,
neuronal network activity, or metabolic triggers and can approach ~10 mM under extreme conditions
such as seizure or hypoxia [4,5]. In principle, the ability to glycolytically process glucose to LL
is shared by astrocytes and neurones, but astrocytes are held to be the main source of LL in the
brain, at least under physiological resting conditions where there is a steeper intra-to-extracellular
LL gradient in astrocytes as compared to neurones [6]. Astrocytes are known to tolerate hypoxic
conditions better than neurones and may more easily upregulate glycolytic activity to bridge periods
of oxygen demand exceeding supply [7]. Indeed, they have been shown to switch to aerobic glycolysis
while sparing the limited oxygen for neuronal oxidative phosphorylation [8]. According to the
astrocyte-to-neuron-lactate-shuttle (ANLS) hypothesis, the astrocyte-derived LL may benefit neurones
as an additional energy substrate to sustain periods of elevated activity [6,9,10].
Whether as a valuable energy substrate or a glycolytic waste product, LL has been reported to
modulate brain activity and behaviour in various functional contexts [5]. LL was shown to be essential
in certain learning and memory paradigms ([11,12]; reviewed in [13]). It is also important for regulating
sleep/wake states at the level of the lateral hypothalamic area, as well as negatively correlating with
sleep-associated slow wave activity in the cortex [14–16]. Moreover, recent evidence suggests that it
acts as an antidepressant in an animal model of depression [17]. Since central cyclic AMP (cAMP)
signalling was found to be reduced in depressed patients, this could potentially be explained by the
ability of LL to increase cAMP responses in astrocytes and some neuronal phenotypes [18–20].
We have previously reported a mechanism that is consistent with, and may contribute to,
LL’s overall role as a central activator and regulator of brain state. We found that optogenetically
induced release of LL from astrocytes into the extracellular space triggers noradrenaline (NA) release
from adjacent noradrenergic neurones [20]. When microinjected into the locus coeruleus (LC) area,
LL desynchronised the electroencephalogram activity in the cerebral cortex, indicating that the
noradrenergic network was excited [20].
It is becoming increasingly clear that LL utilises a wide variety of signaling mechanisms to
influence physiological outputs. These include not only multiple intracellular targets but also effects
on putative receptors located on the plasma membrane of the cells.
1.1. Targets and Mechanisms of L-Lactate Signalling in the Brain
Upon import into neurones, LL can be reduced to pyruvate, raising the NADH/NAD+ ratio
and switching on NMDA receptor-dependent immediate early gene expression ([21]; Figure 1).
This pathway has been suggested to underlie some of the effects of ANLS, for example, memory
formation [13]. A distinct pathway that may allow LL to exert long-term effects is via binding to and
stabilizing the protein NDRG3 which, in turn, activates kinase activity in favour of Raf-Extracellular
signal-regulated kinase signalling to support the tissue response to prolonged hypoxia [22].
In terms of reversible short-term metabolic signalling by LL, ATP-sensitive potassium channels
have been suggested as an intracellular target. Analogous to the scenario in pancreatic beta cells,
inhibition of these channels by LL-derived ATP increased excitation of orexin neurones in the
hypothalamus during arousal [14,23].
In some instances, however, the effects of LL are not consistent with an intracellular action but can
only be explained by activation of membrane-associated receptors from the extracellular side. The first
specific LL receptor to be characterised was the G-protein coupled receptor (GPR) GPR81, currently
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known as hydroxy-carboxylic acid receptor 1 (HCA1). Over recent years, further LL membrane
receptor candidates have been identified, and the list is likely to lengthen (Figure 1).N uroglia 2018, 1, x FOR PEER REVIEW  3 of 16 
 
 
Figure 1. Summary of potential L-lactate (LL)-mediated signalling actions in neurones. L-lactate which 
is transported into the cell can be metabolised and/or influence gene expression, e.g., via NMDA 
receptor modulation or ERK pathway activation. Increased ATP production can inhibit KATP channel 
activity and increase cell excitability. LL may also act via a range of surface G-protein coupled 
receptors to stimulate or inhibit cAMP-dependent signalling, such as NA release in noradrenergic 
neurones. Black arrows indicate stimulatory action, red lines illustrate inhibitory effect. AC—
adenylate cyclase; ERK(P)—phosphorylation of extracellular signal–regulated kinases; GPR4—
orphan G-protein-coupled receptor 4; HCA1—hydroxy-carboxylic acid receptor; LL-OR—LL-
activated olfactory receptor; LLRx—LL receptor on noradrenergic neurones; [mit]—mitochondria; 
NA—noradrenaline; NMDAR—NMDA receptor. 
1.2. Hydroxy-carboxylic acid receptor (HCA1) 
HCA1 was the first G-protein-coupled receptor (GPCR) to be described that is activated 
selectively by LL and a few related monocarboxylates (Table 1). In adipocytes where HCA1 was 
discovered, this leads to inhibition of lipolysis under conditions of glucose abundance in the fed state 
[24,25]. It has been reported that HCA1 is also expressed at low levels in the brain, predominantly in 
neurones, in cerebellum, hippocampus, and neocortex [26]. We carried out RNA sequencing on 
samples of neurones dissociated from the LC of rats and were unable to confirm its expression in 
these cells (Table 2). HCA1 is a Gi-protein-coupled receptor and its activation inhibits cAMP 
production (IC50 in vitro according to various sources is between 5–30 mM; [25–27]. The stereoisomer 
of LL, D-lactate (DL), also a weak agonist at HCA1 (Table 1; [25]). 
In spite of its low potency, site-directed mutagenesis and molecular modelling predicts that LL 
binds specifically as a typical GPCR ligand rather than an allosteric modulator [25]. Being a Gi-
coupled receptor, HCA1 should evoke inhibitory effects (hyperpolarisation of the membrane and 
inhibition of transmitter release), which is opposite to what we found in noradrenergic neurones 
([20]; Figure 1). In cultured embryonic cortical neurones, LL inhibited Ca2+ signalling in a pertussin 
toxin-sensitive manner with a half-maximal inhibitory concentration (IC50) of ~5 mM [28]. Since this 
effect was mimicked by the HCA1 agonist 3,5-dihydroxybenzoic acid (3,5-DHBA), it was indeed 
consistent with signalling via HCA1.  
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Table 1. Characteristics of the known L-lactate receptors.
Receptor LL Potency(Range)
Intracellular
Signalling Other Agonists Antagonists References
HCA1 5–30 mM Gi, cAMP↓ 3,5-DHBA; α-HBA;glycolate; γ-HBA nd [25,26]
OR51E2 ~4 mM Gs, cAMP↑ Acetate;propionate nd [29]
GPR4 1–10 mM allostericmodulation? H
+ NE 52-QQ57 [30]
LLRx 0.5 mM Gs, cAMP↑
MPA; aHIBA;
HMBA; 2HPA; KA
(see Figure 2)
D-lactate [20]
3,5-DHBA (3,5-dihydroxybenzoic acid), α-HBA (α-hydroxybutyrate), γ-HBA (γ-hydroxybutyrate); aHIBA
(α-hydroxyisobutyric acid), HMBA (2-hydroxy-3-methyl-butyric acid), 2HPA ((S)-2-hydroxypentanoic acid,
MPA ((S)-(−)-2-methoxy-propionic acid), nd—not determined, LL—L-lactate. LLRx—putative LL receptor
on noradrenergic neurones, GPR4—orphan G-protein-coupled receptor 4; OR51E2—LL-sensitive olfactory
receptor; HCA1—Hydroxy-carboxylic acid receptor; Gi—Gi-protein activation; Gs—Gs-protein activation;
KA—kynurenic acid.
Table 2. Expression of known L-lactate receptors in locus coeruleus neurones and astrocytes as
determined by RNA sequencing.
Gene Product of Interest LC (p29) LC (p7) LC Neurones Astrocytes
DbH 43.3 527.7 3556.2 2.5
α2A-AR 116.8 307.0 268.4 115.9
HCA1 0.0 0.0 0.0 0.0
OR51E2 7.6 21.3 0.0 0.0
GPR4 70.5 26.0 34.6 24.5
Dopamine-β-hydroxylase (DbH), shown for reference as a marker of noradrenergic neurones, is highly expressed in
locus coeruleus (LC) tissue from 29- and 7-day-old rats, and in dissociated noradrenergic neurones (area A6) from
organotypic brain cultures. Values for a canonical GPCR, α2A-adrenoceptor (α2A-AR), provide a reference for the
expression levels of this class of proteins. In comparison, known L-lactate receptors are found at low to negligible
levels and not specifically on LC neurones. Numbers represent average FKPM (fragments per kilobase of exon per
million fragments mapped) from duplicates. GPR4—orphan G-protein-coupled receptor 4; OR51E2—LL-sensitive
olfactory receptor; HCA1—Hydroxy-carboxylic acid receptor.
1.3. Olfactory L-Lactate Receptors
More recently, OR51E2, a further LL-activated GPCR, has been reported in the mouse. OR51E2
belongs to the family of olfactory receptors which invariably couple to a specific subset of Gs-proteins,
thereby increasing cAMP levels (Figure 1). The EC50 for cAMP elevation in vitro by LL was determined
as 4 mM (Table 1; [29]). As expected, the OR51E2 receptor is found in the rodent olfactory bulb but
it is also ectopically expressed in brain and periphery, for example, in glomus cells in the carotid
body where its role in activation of carotid sinus nerve activity by LL is currently debated [29,31,32].
Olfactory receptors that are LL-sensitive may be involved in the maladaptive increase in sympathetic
drive associated with the progression of chronic heart failure, in a vicious circle that leads to further
deterioration of ischemic conditions and lactate acidosis [33,34].
Ectopic localisation of this olfactory receptor also extends to autonomic ganglia and to the brain,
predominantly brainstem areas [35,36]. Since we previously showed that Gs-coupling was involved
in LL-mediated stimulation of noradrenergic transmission [20], we checked our transcriptomic data
and found OR51E2 expression in LC tissue, but were unable to confirm its expression in isolated LC
neurones (Table 2). We suggest that, since expression levels are low and the receptor appears to be not
specifically localised to noradrenergic neurones, it is unlikely to account for the central effects of LL
we had described earlier.
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Nevertheless, in a study to follow up olfactory perception of LL, we discovered that not only mice
but also humans can detect the odour of LL. However, OR51E2 knockout mice were still able to smell
it [37]. This points to the existence of one or more additional LL-sensitive olfactory receptors which,
if also expressed in the brain, would be expected to contribute to cAMP-mediated LL signalling. At the
same time, olfactory receptors are notorious for their broad spectrum of activating ligands and are
expected to act cooperatively to identify specific odorants.
1.4. Orphan G-protein-coupled receptor 4 (GPR4)
Since LL is one of the main extracellular organic acids, we investigated whether a proton-sensitive
Gs-protein-coupled receptor, GPR4, may mediate or be modulated by LL ([38]; Figure 1, Table 1).
Our evidence suggested that GPR4 contributes to the compensatory ventilatory response to increased
CO2 levels in hypercapnic conditions. However, we found that, under physiological blood and brain
LL concentrations, GPR4 is partially inhibited by LL and its sensitivity to protons is reduced [30].
GPR4 is prominently expressed in the endothelium of blood vessels, in periphery as well
as brain [30]. Localisation in certain neuronal phenotypes such as in retrotrapezoid and raphe
nuclei, rostral ventrolateral medulla, septum, and LC in the mature rodent brain has also been
demonstrated [30,39]. We detected a low level of expression in the LC (Table 2). However, since LL
appears as a negative, presumably allosteric, modulator of GPR4-mediated cAMP production, it cannot
be responsible for the effects of LL we observed on noradrenergic neurones [20]. Considering the
comparatively minor impact of GPR4 on cardiorespiratory regulation and its wide distribution in the
brain, including the raphe nuclei and related areas, it may be modulating processes mediated by these
areas, an issue which remains to be investigated [30]. In setting the cAMP tone and levels of neuronal
excitability it might, for instance, be involved in regulation of anxiety and depression.
1.5. The L-Lactate Receptor Responsible for Central noradrenaline Release
The receptor that mediates the effect of LL-induced NA release (LLRx) in the brain has not been
identified to date. Our previous findings defined several properties for LLRx-mediated NA release
([20]; Figure 1): LL activates LLRx from the extracellular side and does not require entry into the
cell. LL has a higher potency, by ~10-fold or more, at LLRx as compared to other so far identified
LL receptors and is activated around the physiologically relevant LL concentrations in the healthy
brain (0.2–0.5 mM). This makes it suitable for picking up physiologically relevant dynamic changes.
The activation of LLRx by LL is inhibited in the extracellular presence of its stereoisomer DL. LLRx is
most likely a Gs-coupled receptor as the effect of its activation depended on adenylate cyclase [20].
Since none of the receptors discussed above fits these requirements, our hypothesis is that
LL activates one of the orphan G-protein-coupled receptors present in the brain and expressed by
noradrenergic neurones. In the current study, we tested an array of LL derivatives for their ability
to mimic the LL effect on NA release in order to further characterise the structural requirements
for agonists of LLRx. In addition to the primary aim of these experiments, i.e., to establish a
structure–activity relationship (SAR) between the LL molecule and LLRx to aid molecular modelling,
a second objective was to lay the basis for antagonist and superagonist development. In addition,
we carried out next-generation sequencing of neurones in the LC and identified orphan GPCRs which
are expressed. We tested a selection of these in heterologous expression systems for their ability to
activate Gs-proteins in response to LL stimulation.
2. Materials and Methods
2.1. Chemicals
Analogues of LL in which carboxyl-, hydroxyl-, or methyl groups were modified
were obtained from commercial sources: 2-hydroxy-2-propan-sulfonic acid from Alfa Aesar
(Heysham, UK); (±)-3-hydroxy-2-methylbutyric acid, 1-hydroxycyclo-propane-carboxylic acid,
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and (S)-tetrahydro-furoic acid from Acros Organics (Thermo Fisher Scientific, Waltham, MA, USA);
and kynurenic acid from Abcam (Cambridge, UK). All other analogues and reagents were obtained
from Sigma-Aldrich (Merck, Darmstadt, Germany), unless stated otherwise. L-Lactate and analogues,
acetate, and pyruvate were diluted in ddH2O, adjusted to pH 7.4, and used at a final concentration
of 2 mM unless otherwise specified. To evaluate blocking by DL, DL was co-applied with LL or LL
analogues at a final concentration of 200 µM.
2.2. Organotypic Brain Slice Preparation
All animal procedures were performed in accordance with the UK Animals (Scientific Procedures)
Act, 1986, and covered by, PPL 30/3121.
Brainstem slice cultures were prepared as described previously [20]. In brief, 6–7-day-old Wistar
rat pups were terminally anaesthetised and decapitated, and the brainstem was immediately removed.
Slices of 200 µm thickness were cut at the level of the LC in ice-cold sterile dissection medium (in mM:
kynurenic acid 1; Hepes 1; glucose 20; MgCl2 10) using a vibrating microtome (7000 smz, Campden
Instruments, Loughborough, UK). Slices were plated onto cell culture inserts (Millicell PICMORG50,
Millipore, Watford, UK) and supplied with 1 mL per well feeding medium (Opti-MEM; 51985-026,
Thermo Fisher Scientific, Loughborough, UK) supplemented with 25% fetal bovine serum, 25 mM
glucose, and 1% penicillin (10,000 units)/streptavidin (10 mL/L)). To visualise noradrenergic neurones
in the LC, we added ~109 TU/mL of the adenoviral vector (AVV) AVV-PRSx8-EGFP, which results in
green fluorescent protein (EGFP) expression under PRSx8 promoter control [40]. To enable visualisation
of astrocytes, an AVV with transcriptionally enhanced glial fibrillary acidic protein (GFAP) promoter
was used to express EGFP (AVV-sGFAP-EGFP; [41]). Slices were kept at 37 ◦C and in 5% CO2 for
7–12 days prior to experiments to allow for AVV-mediated protein expression.
2.3. Fluorescence-Activated Cell Sorting and RNA Sequencing of Locus Coeruleus Neurones and Astrocytes
Organotypic brain slices including LC were transduced with AVV-PRSx8-EGFP or
AVV-sGFAP-EGFP. The LC area was dissected, and cells were dissociated as described previously [42],
with modifications. The tissue was first digested at 37 ◦C for 10 min in 5 ml of Hank’s Balanced
Salt solution (HBS) in mM: 136 NaCl, 5.3 KCl, 4.1 NaHCO3, 1.6 CaCl2, 0.8 MgSO4, 0.44 KH2PO4,
0.13 Na2HPO4, 10 HEPES, 5.5 D-glucose) containing 30 U of papain (Sigma-Aldrich / Merck,
Darmstadt, Germany) under orbital shaking, before washing off the papain and triturating with
a fire-polished Pasteur pipette. Cells were gently pelleted (3 min, 900 rpm), resuspended in HBS,
and filtered through a 50 µm mesh. EGFP-positive cells were sorted using 488 nm laser excitation and
510–550 nm emission in a Becton Dickinson InFlux cell sorter (BD Biosciences, Franklin Lakes, NJ, USA)
running BD Software version 1.2. Viable cells were identified based on light scatter and the exclusion
of propidium iodide. In addition, single-cell gating was used to exclude doublets and aggregated cells.
Following fluorescence-activated cell sorting (FACS), more than 100 cells were collected into 100 µL
of 2% Triton in phosphate-buffered saline containing 1 µL RNAseOUT (Invitrogen, Thermo Fisher
Scientific, Loughborough, UK), and stored at −80 ◦C until processed further.
Sequencing libraries for next-generation sequencing (NGS) were prepared with 250 ng of total
RNA using Illumina’s Truseq RNA Sample Preparation Kit v2 (Illumina, Inc., San Diego, CA, USA)
following the manufacturer’s protocol. Final PCR-enriched fragments were validated on a 2200
TapeStation (Agilent Technologies, Santa Clara, CA, USA) and quantitated via qPCR using Kapa’s
Library Quantification Kit (Kapa Biosystems, Wilmington, MA, USA) on the QuantStudio 6 Flex
Instrument (Thermo Fisher, Waltham, MA, USA). The final library was sequenced by 50 bp paired-end
sequencing on a HiSeq 2500 (Illumina). Illumina BCL files were converted and demultiplexed (bcl2fastq
2.17). FASTQ files were trimmed of adapter sequences (CutAdapt 1.8.3) and aligned to rn5 (STAR
2.5). Aligned reads were summarised as gene-level counts (featureCounts 1.4.4) and as transcripts per
million (Kallisto 0.43.0). Sequencing and quality control reports were generated (FastQC 0.11.4 and
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Qualimap 2.1.3). Pairwise differential expression analysis was conducted with the R package DESeq2
(1.10.1)
2.4. Measurement of Noradrenaline Release
In our earlier study, we used fast scan cyclic voltammetry to detect NA release in organotypic
slices of the LC in response to LL stimulation. Here, in order to expand selection of LL analogues
tested and to increase throughput, we implemented an approach based on cell-based neurotransmitter
fluorescent engineered reporter cells (CNiFERs; Supplementary Materials Figure S1) [43]. CNiFERs
are derived from a HEK293 cell line that stably expresses the Ca2+ indicator TN-XXL and a human
α1 adrenoreceptor. Binding of NA to the adrenoceptor activates Gq-protein signalling, leading to
an increase in cytosolic Ca2+ through the phospholipase C-inositol triphosphate pathway which is
imaged through the FRET ratio of TN-XXL (Supplementary Materials Figure S1A,B). CNiFERs showed
nanomolar sensitivity to NA (EC50 = 31 ± 1.75 nM).
To monitor NA release from organotypic brain slices, 4 × 105 CNiFERs were plated 24 h prior
to experiments on a cell culture insert (Supplementary Materials Figure S1C). Imaging experiments
were performed at 34 ◦C under continuous perfusion (150 mL/h) with HEPES-buffered solution (HBS,
pH 7.4; in mM: NaCl 138; KCl 5.5; Na2HPO4 0.25; KH2PO4 0.5; CaCl2 1.67; MgSO4 0.8; NaHCO3
4.25; HEPES 10; Glucose 5.5) in a tissue chamber mounted on a Leica SP5 confocal microscope.
Images were collected in a time-lapse mode (0.25 Hz) with excitation at 458 nm and dual emission
set to 462–501 nm (Citrine) and 519–595 nm (ECFP). Fluorescence intensities of Citrine and ECFP
channels were exported and analysed offline in Excel (Microsoft, Redmond, WA, USA). The FRET ratio
(ECFP/Citrine) was calculated, plotted against time, and the area under the curve (AUC) following
LL/analogue stimulation was determined as FRET ratio x s. CNiFER responses were calibrated against
100 nM NA to allow evaluation of total NA release in nM x s.
2.5. Patch Clamp of Noradrenergic Neurones
Cultured slices containing the LC and transduced with an AVV-PRSx8-eGFP were transferred
to a recording chamber mounted on an upright SP-2 confocal microscope (Leica, Wetzlar, Germany)
and continuously superfused with HEPES-buffered solution (in mM: NaCl 137, KCl 5.4, Na2HPO4
0.25, KH2PO4 0.44, CaCl2 1.3, MgSO4 1.0, NaHCO3 4.2, HEPES 10, Glucose 5.5; pH 7.4) at 34 ± 1 ◦C.
Current-clamp whole-cell recordings were sampled at 10 kHz using an AxoClamp 2B amplifier
(Molecular Devices, San Jose, CA, USA) and a 1401 interface with Spike 2 software (CED, Cambridge,
UK). Recording pipettes were pulled with a vertical puller (Narishige PC-10) to 3–5 MΩ resistance and
filled with pipette solution (in mM: potassium gluconate 130, HEPES 10, EGTA 5.5, NaCl 4, MgCl2 2,
CaCl2 1, ATP 2, GTP 1, and glucose 5). After recording 5–10 min of stable baseline in current clamp, LL
or its analogues were superfused with the chamber solution for 5–10 min.
2.6. GloSensor Assay of Intracellular cAMP Accumulation
Clones of a selection of human orphan GPCR open reading frames were commercially obtained:
GPR61 and GPR176 from cDNA Resource Center (www.cdna.org); GPR81, GPR137, GPR137B, GPR158,
GPR180 from SourceBioScience (www.sourcebioscience.com); GPR155 from Origene (www.origene.
com); rodent GPR162 was synthetised by Eurofins Scientific (www.eurofins.co.uk). The open reading
frames of the receptors were cloned into the expression plasmid pEGFP-N1 under control of the
human cytomegalovirus promoter, upstream of a human internal ribosomal entry site, followed by the
enhanced green fluorescent protein sequence.
The GloSensor assay was used for cAMP measurements as previously described,
with modifications [42]. HEK293 cells were plated in 96-well white polystyrene plates (Greiner Bio-One,
Kremsmünster, Austria) in DMEM media (Gibco, Thermo Fisher Scientific, Loughborough, UK)
supplemented with 10% fetal bovine serum and 1% penicillin (10,000 units)/streptavidin (10 mL/L)),
at a density of 4 × 105 cells/mL to achieve ~70% confluence for transfection. After 20 h, cells were
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transiently co-transfected with the GloSensor cAMP plasmid GLO22F and a plasmid encoding the
GPCR of interest using Trans-IT 293 (Mirus) according to the manufacturer’s protocol. Transfection
efficiency was confirmed by fluorescent visualisation of EGFP. Twenty-six hours after the transfection,
cells were incubated with 850 µM beetle luciferin potassium salt (Promega, Southampton, UK) at pH
7.4 for 2 h in the dark. Prior to adding drugs, media was changed to HBS (Gibco) buffered with 20 mM
HEPES and titrated to the desired pH. Cells were incubated with LL for 20 min in a final well volume
of 100 µL. Luminescence measurements of cAMP accumulation were obtained using an Infinite M200
PRO microplate reader (Tecan, Männedorf, Switzerland).
2.7. Statistical Analysis
Data are expressed as mean ± standard error of the mean (SEM). Groups were compared using
Student’s t-test or one-way ANOVA as indicated. GraphPad Prism (version 7; La Jolla, CA, USA) was
used for data processing and to calculate EC50.
3. Results
3.1. L-Lactate Releases Noradrenaline from Locus Coeruleus Neurones
To detect LL-induced release of NA we used a cell-based reporter system developed in D.
Kleinfeld’s laboratory [43]. These “α1 CNiFER” cells respond with a robust Ca2+ increase to NA
which is registered through a ratiometric Ca2+ indicator which they express. Consistent with our
previous observations using fast-scan cyclic voltammetry, a transient change in α1 CNiFER cell signals
confirmed that LL (2 mM) evokes NA release from LC neurones in organotypic slices. As we previously
reported, this effect was blocked by DL (200 µM) and was independent of the caloric value of LL since
neither pyruvate nor acetate (2 mM) triggered NA release [20] (Supplementary Materials Figure S1D).
3.2. Structural Requirements for the Agonistic Action of L-Lactate on Noradrenaline Release
In order to characterise the structural features required for LL binding to LLRx, we chose
commercially available LL analogues in which the carboxyl, hydroxyl, or methyl groups were modified
(Figure 2A–D). In addition, the effect of chain extension by increasing the distance between the OH and
the carboxylate group of LL (e.g., 4, Figure 2C) or replacing the methyl group of LL with longer alkyl
(9, 10) or aralkyl chains (13–15, Figure 2D) was studied. Conformational restriction by carbocyclic (5)
or heterocyclic ring (7, 11) formation was also investigated (Figure 2C,D). Each analogue was tested at
2 mM for its ability to evoke NA release, and the response was normalised to the effect of equimolar
LL tested in the same slice (Figure 2E).
L-lactate analogues with modified carboxyl (1), hydroxyl (3), and methyl groups (8–10 and 15) and
the heterocyclic analogues (7 and 11) stimulated NA release; however, none of these were significantly
more efficacious than LL (Figure 2E). All other test compounds (2, 4–6, 12–14) evoked significantly
smaller responses, leading to less than 50% of the NA release triggered by LL application (Figure 2E).
We then further focused on the 8 active LL analogues to test for antagonistic properties of DL, and found
that analogues (S)-(−)-2-methoxypropionic acid (3, MPA; Figure 2C), α-hydroxyisobutyric acid
(8, aHIBA; Figure 2D), 2-hydroxy-3-methylbutyric acid (9, HMBA; Figure 2D), (S)-2-hydroxyl-pentanoic
acid (10, 2HPA; Figure 2D), and kynurenic acid (11, KA; Figure 2D) fulfilled the criteria for mimicking
the effect of LL on NA release (Figure 2F; [20]).
We have previously shown that the effect of LL on NA release was paralleled by depolarisation
of noradrenergic neurones, increasing their excitability [20]. In the current set of experiments,
we extended this dataset and compared resting membrane depolarisation caused by LL with the
effect of LL analogues (Table 3; Supplementary Materials Figure S2). L-lactate, aHIBA (8, Figure 2D),
and HMBA (9, Figure 2D) caused depolarisation in a significant proportion of neurones. However, MPA
(3, Figure 2C), 2HPA (10, Figure 2C), and KA (11, Figure 2C), also powerful NA-releasing LL mimetics,
Neuroglia 2018, 1 373
evoked no depolarisation (Tables 1 and 3), suggesting that in noradrenergic neurones, depolarisation
and cAMP-dependent transmitter release evoked by LL are not coupled in an obligatory way.Neuroglia 2018, 1, x FOR PEER REVIEW  9 of 16 
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L-lactic (LL) acid molecule. The selection of tested LL analogues had alterations in the carboxyl
group (B) (yellow highlight), in the hydroxyl group (C) (red hi hlight); and in the methyl group (D)
(blue highlight). (E) LL analogues 1, 3, 7, 8–11, and 15 (2 ) triggered more than 50% response
in noradrenaline-sensitive α1 CNiFER cells as compared to 2 mM LL (100%). The rest of the tested
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Table 3. Depolarisation of locus coeruleus neurones evoked by L-lactate and its analogues that cause
D-lactate-sensitive noradrenaline release.
LL Analogue (Figure 2) Cells Analysed (number) Cells Depolarised (%) Vm (mV)
LL 94 34 7.3 ± 1.1
3 8 0
8 28 43 6.2 ± 1.3
9 9 67 5.3 ± 1.0
10 8 25
11 7 14
L-lactate (LL) analogue numbers as displayed in Figure 2. Resting membrane potential data (Vm) are displayed as
mean ± SEM in cells that showed a response.
3.3. Orphan GPCRs as Putative Targets of L-Lactate
We used the DiscoveRx panel of orphan GPCRs (orphanMAX, LeadHunter; Fremont, CA, USA)
to screen for the activity of LL (2–8 mM) and filtered the results for those orphans that were expressed
in the LC, based on our NGS data (Table 4).
Only one of the orphan receptors on the panel, GPR162, satisfied the DiscoveRx criteria of >30%
for significant activation by LL (at 8 mM). The response of several other receptors, however, exceeded
3 times the standard deviation of the baseline. Note that HCA1 (GPR81) did not respond to the
maximum concentration of 8 mM LL as employed in our DiscoveRx screen, indicating that this assay
might not be suitable for detection of signalling through these low-affinity receptors.
We considered those orphan GPCRs with likely Gs-protein or unknown coupling that were
expressed in noradrenergic neurones of the LC, but not in astrocytes, for further testing (Table 4).
Receptors were transiently expressed in HEK293 cells and subjected to the GloSensor cAMP assay to
test for the response to LL (Table 4; Figure 3). As expected, HEK293 cells transiently transfected with
GPR81 showed a concentration-dependent reduction in cAMP accumulation when stimulated with LL
(Figure 3A). Another orphan receptor, GPR180, responded with decrease in cAMP to both 1 mM and
10 mM LL (Figure 3B). The only orphan receptor to significantly increase cAMP production with LL in
the range of 1–5 mM was GPR137 (Figure 4A,C). In contrast, its paralogue, GPR137B, which is also
highly expressed in noradrenergic cells of the LC, did not respond to 2 mM LL (Figure 4B).
The enantiomer of LL, DL (0.4 mM), did not activate GPR137 to increase cAMP production
(Figure 4C). Co-application of 0.4 mM DL with 2 mM LL, which in our previous study blocked
LL-evoked effects on NA release, did not significantly affect cAMP accumulation in comparison to
2 mM LL application alone (Figure 4C).
Table 4. Screening of heterologously expressed orphan GPCRs for activation by L-lactate.
DiscoveRx Activation
(%) by LL (mM) Expression in LC (NGS)
cAMP Assay:
Activation by LL
(0.5–10 mM)GPCR Coupling? 2 4 8 p29 p7 Neuron Astrocyte
GPR61 Gs −2% 16% 19% 97 183 163 0 No response
GPR81 Gi 1% 3% 3% 0 0 0 0 Decrease
GPR137 Gs? 6% 4% 3% 959 628 196 577 Increase
GPR137B ? nd nd nd 226 83 140 125 No response
GPR146 ? −3% 10% 20% 129 49 6 312 nd
GPR155 RGS? nd nd nd 842 412 140 36 No response
GPR158 RGS7 nd nd nd 1692 433 613 1 No response
GPR162 ? −9% 15% 30% 1293 1012 282 64 No response
GPR176 Gz −8% −2% 9% 193 196 190 9 No response
GPR180 Gi? nd nd nd 768 542 520 83 Decrease
The combination of DiscoveRx panel readout and GloSensor assay for cAMP production suggests further L-lactate
(LL)–sensing GPCR candidates. Apart from GPR81, this selection of receptors is expressed in locus coeruleus (LC)
neurones at medium to high levels. Coupling information obtained from www.genecards.org. NGS–RNA-Seq by
next-generation sequencing; nd—not determined.
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Figure 3. L-lactate activates GPR81- and GPR180-dependent Gi-protein signalling in HEK293 cells.
(A) L-lactate (LL) concentration-dependently decreases cAMP accumulation in HEK293 cells transiently
transfected with GPR81 (0.1 µg/µL; GloSensor assay; EC50 243 µM). In order to create an elevated cAMP
baseline level, cells were pretreated with 20 µM NHK 477, a soluble forskolin analogue. (B) Selected
orphan GPCRs present in locus coeruleus neurones were transiently expressed in HEK293 cells
(transfection with 0.1 µg/µL GPCR expression plasmid). Application of LL led to a significant decrease
in cAMP only in GPR180-expressing cells. GloSensor assay: luminescence normalised to baseline in
absence of LL; data represented as mean ± SEM; ** p < 0.01, * p < 0.05 vs no LL stimulation; n = 3;
one-way ANOVA with Dunnett’s as post-hoc test.
4. Discussion
This study aimed to further characterise LLRx, the LL receptor which mediates the communication
between activate astrocytes and noradrenergi neurones [20]. Our previous evidence ad suggested
that LL acts t a extrac llul r site and was not co sistent with the mod lation of KATP channels.
Based on the sensitivity of the effect to inhibition of adenylate cyclase or protein kinase A,
we hypothesised that LLRx is most likely a GPCR that activates Gs-protein signalli g, suggestiv of an
orphan GPCR or one of th olfactory receptors.
The potency of LL via its actio on LLRx (EC50 ~0.5 mM) should be low compared to that of
other endogenous GPCR ligands. For example, NA acting at β-adrenoceptors is around thre orders of
magnitude more potent (see Supplement in [44]. It is, however, fully consist n with a specific response
based on low-affinity binding, giv n the high physiological extracellular LL concentration in the brain.
Ind ed, in comparison to the other LL receptors reported to date, HCA1 and OR51E2, the EC50 of LL
at LLRx is round 10-fold l wer and appears well correlated with the operational range of brain LL
conc ntrati ns. It is, therefo e, most suitable for me iating a dynamic physiological res onse to LL.
The experimental disadvantage of a low-affinity ligand–receptor teraction is that it rules
out ecific pull-down approaches to concentrate and biochemically analyse the receptor. Hence,
we adopted an alternative approach to eva uate the properties of the LL–LLRx i teraction and t
determine an agonist profile for the LLRx-mediated stimulation of NA release.
The carboxyl group seems to be ssential for LL’s agonist activity as it was intact in all
NA-r leasing anal gues, and methylation of the carboxyl group to form the ester analogue M-LL
abolished the effect (2, Figure 2B,E,F). Replacement of the c rboxyl group by a more acidi sulfonate
group in HPSA (1, Figure 2B) did result i triggering NA release, but elimina ed the ant gonist ffect
of DL. T is suggests hat HPSA acts via a different mechanism than by activation f LLRx. Indeed,
it may be that HPSA is decomposing into acetone and sulphuric acid, lead ng to a fals positive result.
The 2-hydroxyl group was intact in most of the active LL analogues, indicating its importance
for NA release. Most analogues with 2-OH deletion or modifications, particularly addition of large
groups, were inactive, apart from MPA, THFA, and KA (3, 7 Figure 2C, 11, Figure 2D, respectively).
The DL-sensitive effect of MPA indicates that the hydroxyl group may act as a hydrogen bond acceptor,
but hydrogen bond donation is not necessary to trigger NA release. THFA (7, Figure 2C) can be
thought of as a conformationally restricted analogue of LL and MPA (3, Figure 2C), while HCPCA
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(5, Figure 2C) is a conformationally restricted analogue of LL and aHIBA (8, Figure 2D). THFA and
HCPCA were less active than the parent molecules MPA and aHIBA, respectively, suggesting that
the conformations of THFA and HCPCA are not optimal for interaction with LLRx. Kynurenic acid
(KA, 11, Figure 2D) can be thought of as a conformationally restricted analogue of LL in which the
NH group acts as a mimic of the OH group of LL and the methyl group of LL is incorporated into the
ring structure. The 4-oxo group of KA, which is a hydrogen bond acceptor, may also play a role in
interacting with LLRx. Future SAR studies are needed to explore this possibility.
Addition of a second methyl group in the α-position, as in aHIBA (8, Figure 2D), or extension of
the carbon chain from the methyl group as in HMBA and 2HPA (9, 10, Figure 2D), supports activation
of LLRx. However, large lipophilic residues replacing or added as substituents to the methyl group
prevent DL-sensitive NA release (12–15, Figure 2D), indicating a limitation of size in the binding pocket.
The comparison of the analogues that cause NA release and those that evoke membrane
depolarisation shows that, in noradrenergic neurones, NA release can be evoked without necessarily
increasing the cells’ electrical excitability. This is unsurprising, given previous evidence for
cAMP-mediated increase in exocytosis [45]. In fact, extensive evidence indicates that depolarisation
should not be the primary mechanism regulating NA release, because noradrenergic neurones are
characteristically depolarised at rest. Membrane potentials of LC neurones, in vitro as well as in vivo,
are typically near −50 mV (Supplementary Materials Figure S2; [20,46–48]. Moreover, LC neurones
in vivo and in slices tend to generate a constant low-frequency stream of action potentials while their
excitation by a sensory stimulus triggers only a very short (~20 ms) barrage of 3–5 additional action
potentials which is followed by a long period of quiescence lasting hundreds of milliseconds [49,50].
Therefore, the conventional logic of neuronal networks where high-frequency action potential activity
triggers release of a neurotransmitter, such as glutamate, does not apply to noradrenergic neurones.
A mechanism which sensitises the NA release machinery and potentiates NA release to the steady-state
level of intracellular Ca2+ (with or without additional depolarisation) should be a much more effective
way to control NA release.
It is also important to note that the chemicals tested here can affect multiple targets. Kynurenic
acid, for example, while effectively triggering DL-sensitive NA release, is also a well-known glutamate
receptor antagonist [51]. Blocking of glutamate receptors theoretically should lead to a decrease rather
than an increase in neuronal excitability, but KA nevertheless triggered release of NA.
Whilst beyond the scope of the current study, analogues that failed to produce a positive response
in the NA release assay may have antagonist or weak partial agonist properties. If such compounds
are identified and optimised, they may be expected to facilitate future studies to characterise the
physiological and pathophysiological roles of this astrocytic signalling pathway.
The DiscoveRx panel screening is based on β-arrestin-induced internalisation and should be
independent of the type of G-protein the receptor couples with. The approach is not very sensitive
and, in the case of low-potency agonists such as LL, relatively high concentrations of agonist need to
be employed, potentially leading to nonspecific effects. Only few concentration-dependent responses
to LL (2–8 mM) were detected. When following up on the effect of LL on GPR162, we were
unable to confirm a LL-induced change in cAMP production in transiently transfected HEK293
cells. This suggests that GPR162 does not signal via Gs-proteins and is therefore not consistent with
LLRx function.
We acknowledge that we selected orphan candidates with medium to high expression levels in
LC and with either unknown or proposed Gs-coupling in order to determine their cAMP response
to LL (Table 4). Of these, only GPR137 produced a concentration-dependent but DL-insensitive
increase in cAMP, making it an interesting candidate for further study. GPR137 has two paralogues,
GPR137B and GPR137C, which are located on different chromosomes. Unusually for GPCRs, all three
paralogues contain introns, raising the possibility of multiple variants through alternative splicing.
GPR137 has been suggested to play a role in the proliferation of malignant tumours, but its functional
significance for the brain has not yet been explored [52,53]. Neither ligands nor physiological actions of
Neuroglia 2018, 1 377
GPR137B and GPR137C are currently established. However, as the cAMP response was not inhibited
by co-application of DL, GPR137 does not fulfil all properties proposed for “LLRx” (Figure 4C).
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Figure 4. L-lact te stimulates GPR137-dependent cA l i i EK293 cells. (A) HEK293
cells transiently transfected with GPR137 (0.01 µg/ ) r s nd to 2 L-lactate ( L) with cAMP
accumulation (GloSensor assay, n = 3, ** p < 0.01 vs baseline ( ), one-way ANOVA with Tukey’s
post-hoc test). (B) HEK293 cells expressing GPR137B do not respond to 2 LL. (C) Concentration
range of LL and DL effects on cAMP in HEK293 cells transiently transfected with GPR137 (0.01 µg/µL).
LL significantly increases cAMP at concentrations ≥ 1 mM. D-lactate (DL) elicits no response and does
not significantly inhibit the effect of 2 mM LL (data are shown as mean ± SEM; n values for each
dataset are represented in the respective columns; **** p < 0.0001, * p < 0.05 vs control, one-way ANOVA
with Tukey’s post-hoc test).
Looking into the future, the list of potential LL receptor candidates is by no means complete if we
include orphan GPCRs with low to medium expression levels such as GPR146 and others (not shown)
to explore further as targets for LL-mediated signalling. Since LL-mediated release of NA is implicated
in regulation of sleep/wake and attention states, learning and memory, and cardiorespiratory control,
a better understanding of—and pharmacological tools to control—this signalling axis may have
significant health implications.
Supplementary Materials: The following are available online at http://www.mdpi.com/2571-6980/1/2/25/s1,
Figure S1. L-lactate evokes noradrenaline release from organotypic brain slices cultures as confirmed by using α1
CNiFER cells. Figure S2. L-lactate and analogues excite noradrenergic LC neurones.
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